IPP Bureau
Zydus receives warning letter from USFDA for Jarod injectables manufacturing facility
By IPP Bureau - August 31, 2024
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
By IPP Bureau - August 31, 2024
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
DKSH partners with Hasten Biopharmaceutical’s growth in Thailand
By IPP Bureau - August 31, 2024
Indian doctor participates in Jordan’s first robotic radical hysterectomies
By IPP Bureau - August 31, 2024
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
By IPP Bureau - August 30, 2024
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split
By IPP Bureau - August 30, 2024
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Natco Pharma announces submission of TABRECTA to USFDA
By IPP Bureau - August 30, 2024
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Ayurvedic Whole System effective in Managing Rheumatoid Arthritis: Study
By IPP Bureau - August 30, 2024
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Suven Life Sciences announces FDA acceptance of investigational new drug
By IPP Bureau - August 30, 2024
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Bayer starts Phase III trial in non-small cell lung cancer
By IPP Bureau - August 30, 2024
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Bayer awards incubator opportunity to Genvor
By IPP Bureau - August 30, 2024
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Lupin receives USFDA approval for Brimonidine Tartrate Ophthalmic Solution, 0.1%
By IPP Bureau - August 28, 2024
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Aptar Closures introduces new lightweight 2? Disc Top Lite Closure for beauty and personal care
By IPP Bureau - August 28, 2024
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Zydus receives USFDA final approval for Amantadine ER capsules 68.5 mg
By IPP Bureau - August 28, 2024
Also received tentative approval for 137 mg
